Innovative Approaches to Investigating KRAS Therapeutics with Biochemical and Cell Based Assays 2

Presented By:
Elodie Dupuis

Speaker Biography:
Elodie Dupuis graduated with a master’s degree in Cellular & Molecular Biology from the University of Nimes & Engineering School, Ecole des mines of Ales. She joined the Cisbio | PerkinElmer research and development team in 2009 and is now an R&D Project Manager and Team Leader focused on developing HTRF® and AlphaLISA® assays and tools in collaboration with the Cisbio-Functional Genomics Institute in Montpellier. Elodie’s team focuses on GPCRs, ion channels, tyrosine kinase receptor signaling, and oncology. She was integral in developing and launching the PerkinElmer portfolio of homogenous KRAS assays, comprising of the following binding kits: KRAS WT GT, KRAS WT/SOS1, KRAS G12C/SOS1, KRAS G12C GTP.

Webinar:
Innovative Approaches to Investigating KRAS Therapeutics with Biochemical Cell-Based Assays

Webinar Abstract:
Kirsten rat sarcoma viral oncogene homologue (KRAS) is the most frequently mutated oncogene, present in approximately 25% of tumors. Numerous studies on KRAS in the initiation and advancement of cancer are constantly updating our knowledge of the gene. Despite drug-targeting attempts over the past four decades, KRAS has been labeled a difficult therapeutic target, even "undruggable”, however, recent advances, such as the FDA approval of Amgen’s sotorasib, exemplifies and encourages new progress in the field. This webinar explores innovative methods to discover and qualify KRAS inhibitors with downstream signaling and binding assays, utilizing no-wash HTRF® and AlphaLISA® technology to further the discovery of drugs targeting KRAS.

LabRoots on Social:
SnapChat: labroots_inc